Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 1/2 2Phase 1 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 2Recurrence 1Disease Progression 1

Interventions

Dexamethasone 129Lenalidomide 70Cyclophosphamide 70Bortezomib 69Calcium Dobesilate 50fludarabine 44pomalidomide 40daratumumab 37carfilzomib 33fludarabine phosphate 31Melphalan 25dexamethasone acetate 20dexamethasone 21-phosphate 20auricularum 18Filgrastim 18Whole-Body Irradiation 14Biopsy 13isatuximab 12Vorinostat 12Tacrolimus 12Peripheral Blood Stem Cell Transplantation 12Magnetic Resonance Spectroscopy 12Granulocyte Colony-Stimulating Factor 12Specimen Handling 11Sirolimus 11ixazomib 10belantamab mafodotin 10Panobinostat 10Mycophenolic Acid 10Cyclosporine 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Multiple Myeloma × Transplantation, Autologous × Clear all
NCT02043847 2024-11-13

BMT-03

University of Illinois at Chicago

Phase 1 Completed
12 enrolled 12 charts
Plasma cell

Multiple Myeloma, Recurrence, Disease Progression

NCT02043860 2019-10-14

BMT-02

University of Illinois at Chicago

Phase 1 Terminated
3 enrolled 5 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡